John D. Shaughnessy Jr.

High Impact

Professor

University of Arkansas for Medical Sciences

faculty

Internal Med, College of Medicine

88 h-index 483 pubs 30,940 cited

Research Areas

Multiple Myeloma Research and Treatments Cancer-related molecular mechanisms research Cancer Immunotherapy and Biomarkers Immune Cell Function and Interaction T-cell and B-cell Immunology Meta-analysis and systematic reviews Health and Medical Research Impacts CAR-T cell therapy research

Links

ORCID Google Scholar Lab Website Research Group UAMS TRI Profile

Is this your profile? Verify and claim your profile

OverviewAI-generated summary

John D. Shaughnessy Jr. is a Professor in the Department of Internal Medicine at the University of Arkansas for Medical Sciences. His research focuses on multiple myeloma, investigating its genetic complexity, progression, and potential therapeutic strategies. Recent publications include work on the risk of infections associated with bispecific antibody use in multiple myeloma, the role of TRIP13 in B cell malignancy development, and the efficacy of bispecific BCMA/CD24 CAR-T cells for controlling myeloma growth. He has also explored how CST6 suppresses osteolytic bone disease in multiple myeloma and how high NEK2 expression in myeloid progenitors impacts T cell immunity in this disease.

Shaughnessy's work extends to understanding the tumor microenvironment, as demonstrated by research on tumor-infiltrating normal B cells in diffuse large B-cell lymphoma (DLBCL) and their prognostic significance for antitumor immune responses. His scholarly contributions are substantial, with a career h-index of 88, over 480 publications, and more than 30,000 citations, recognizing him as a highly cited researcher. He actively leads a research group and collaborates with colleagues at the University of Arkansas for Medical Sciences, including Fenghuang Zhan, Guido Tricot, Clyde Bailey, and Sharmilan Thanendrarajan, with whom he has co-authored numerous publications.

Metrics

h-index: 88
Publications: 483
Citations: 30,940

Selected Publications

Peripheral blood immune cell profiling and response to BCMA CAR-T cell therapy in relapsed refractory multiple myeloma (2026) DOI
Polyclonal plasma cell (PolyPC) signature as a key indicator for predicting the progression of MGUS to multiple myeloma (2025) DOI
Long-Term Follow-Up of Patients With Multiple Myeloma Treated on Earlier Total Therapy Protocols (2025) DOI
Cystatin M/E Ameliorates Multiple Myeloma-Induced Hyper Osteolytic Bone Resorption (2025) DOI
Prior exposure to belantamab mafodotin influences outcomes with idecabtagene vicleucel in patients with multiple myeloma (2025) DOI
Targeting caseinolytic mitochondrial matrix peptidase, a novel contributor to the pathobiology of high-risk multiple myeloma (2025) DOI
Single-cell analysis of neoplastic plasma cells identifies myeloma pathobiology mediators and potential targets (2025) DOI
Long-term follow-up of Total Therapy IV: a phase 3 clinical trial for standard-risk multiple myeloma (2024) DOI
Multi-Omics Reveal Immune Microenvironment Alterations in Multiple Myeloma and Its Precursor Stages (2024) DOI
Psychological Impact in Individuals with Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma (2024) DOI
A Risk Stratification System in Myeloma Patients with Autologous Stem Cell Transplantation (2024) DOI
Enhancing prognostic power in multiple myeloma using a plasma cell signature derived from single-cell RNA sequencing (2024) DOI
Prognostic value of ferritin in ASCT MM patients: integration with GEP models and ISS series systems (2024) DOI
Development and validation of an individualized and weighted Myeloma Prognostic Score System (<scp>MPSS</scp>) in patients with newly diagnosed multiple myeloma (2024) DOI
Bispecific BCMA/CD24 CAR-T cells control multiple myeloma growth (2024) DOI

Grants & Funding

Developmental Funds Pilot of the Southwest Oncology Group-SWOG-01047 NIH/Nat. Cancer Institute Principal Investigator
Gene expression profiling vs MRD assessment in Myeloma NIH Co-Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Studying the role of APRIL and BAFF signaling in Myelomagenesis and its Therapy ZymoGenetics, Inc Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator
Molecular Diagnosis and Prognosis of Multiple Myeloma NIH/Nat. Cancer Institute Principal Investigator
U54 - Bioinformatics Core NIH/Nat. Cancer Institute - Pass Through: Baylor College of Medicine Principal Investigator
Preclinical Studies of the Mechanisms of Action of Velcade Millennium Pharmaceuticals, Inc. Principal Investigator